Vall d’Hebron Institute of Oncology - Breast cancer

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer.

We have generated an extensive experimental resource of PDXs from primary and metastatic breast tumours, aiming to tackle drug resistances and find new therapies.

The Vall d’Hebron Institute of Oncology is a member of the EurOPDX Consortium. EurOPDX is supported by the European Union's Horizon 2020 research and innovation programme under the grant agreement No. 731105 EDIReX